Results 291 to 300 of about 427,029 (392)

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Identification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia. [PDF]

Int J Mol Sci
Ozer Yaman S, Petrović N, Yaman S, Akidan O, Cimbek A, Baycelebi G, Srdić-Rajić T, Šami A, Misir S.   +8 more
europepmc   +1 more source

Characterizing and assessing vision‐related quality of life among patients discontinued treatment for neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose This study characterized and assessed vision‐related quality of life (VRQoL) in patients with neovascular age‐related macular degeneration (nAMD) who discontinued treatment with intravitreal anti‐vascular endothelial growth factor (anti‐VEGF), comparing them to those undergoing treatment.
Noreddin Shekho, Anna Stage Vergmann, Frederik Nørregaard Pedersen, Lonny Stokholm, Benjamin Sommer Thinggaard   +4 more
wiley   +1 more source

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia. [PDF]

Leukemia
Curik N, Laznicka A, Krizkova J, Suchankova P, Vavrova A, Polivkova V, Pokorna E, Semerak P, Burda P, Kuzilkova D, Kalina T, Hochhaus A, Machova Polakova K.   +12 more
europepmc   +1 more source

Impact of additional cytogenetic aberrations at diagnosis of chronic phase chronic myeloid leukemia. [PDF]

Ther Adv Med Oncol
Cheng F, Cui Z, Li Q, Tong J, Li W.
europepmc   +1 more source

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.

Blood, 2017
TaeHyung Kim, Marc S. Tyndel, Hyeoung-Joon Kim, Jae-Sook Ahn, S. Choi, H. Park, Yeo-Kyeoung Kim, Soo Young Kim, J. Lipton, Zhaolei Zhang, Dennis (Dong Hwan) Kim   +10 more
semanticscholar   +1 more source

Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study

British Journal of Haematology, EarlyView.
In a population‐based cohort of 149 chronic myelomonocytic leukaemia (CMML) patients, multihit TET2 mutation was associated with older age, lower LDH and less leucocytosis. We found no association with autoimmune disease or thrombosis. Patients with multihit TET2 mutation had a significantly longer overall survival than the patients without or with one
Matilda Kjellander Kynning, Ebba Westerberg, Linda Forsell, Maria Creignou, Daniel Moreno Berggren, Bianca Tesi, Elsa Bernard, Elli Papaemmanuil, Yasuhito Nannya, Lucia Cavelier Franco, Davide Valentini, Eva Hellström Lindberg, Seishi Ogawa, Elisabeth Ejerblad, Johanna Ungerstedt   +14 more
wiley   +1 more source

Chronic Myeloid Leukemia in a Young Adult. [PDF]

Cureus
Patel K, Syed J, Jagadish A, Vedantam V, Daugherty D.   +4 more
europepmc   +1 more source

Burden of haematological malignancies among children, adolescents and young adults: Global and high‐income region insights from the GBD 2021 study

British Journal of Haematology, EarlyView.
Summary This study provides a comprehensive assessment of haematological malignancies among children, adolescents and young adults aged 0–24 years, using data from the Global Burden of Disease 2021 across 204 countries from 1990 to 2021. We found that global incidence and prevalence remained relatively stable, with approximately 150 000 new cases and ...
Shujuan Xu, Baihua Yang, Xinxin Liu, Zhenshu Xu, Ping Weng   +4 more
wiley   +1 more source